ArticleFrontiers in neurology2025
Epidemiology and treatment patterns of essential tremor: a retrospective cohort analysis in Germany.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Real-world evidence on the epidemiology, clinical characteristics, and treatment patterns of patients with essential tremor (ET) is limited. We used data from two large representative German claims databases to address this evidence gap. Methods: Data were obtained from two German statutory health insurance databases, AOK PLUS and GWQ ServicePlus, from January 1, 2010 to March 31, 2022. Point prevalence and cumulative incidence of ET, standardized by age and sex to the German national population, were assessed. Baseline demographics, clinical characteristics, and treatment patterns were described within a cohort of patients newly diagnosed with ET in each database. Time to treatment initiation from diagnosis, and discontinuation and switch from the first-line therapeutic approach were evaluated using Kaplan Meier methods. Results: Age and sex-standardized prevalence of ET increased between 2010 and 2021, reaching 196 (AOK) and 250 (GWQ) per 100,000 persons in 2021. Among patients newly diagnosed with ET, the most frequent comorbidities at baseline were pain disorders (65-70%), hypertension (44-65%), and hyperlipidaemia (30-35%). Approximately 60% of patients received pharmacological therapy during follow-up (mean 56-62 months), particularly propranolol (44-50%), bisoprolol (24-27%) and metoprolol (23-27%). The median time from diagnosis to treatment initiation was 2.1-6.3 months. Most patients discontinued (72-75%) their first therapy within 12 months, with 41-46% switching to another therapy. Conclusion: ET is a common movement disorder, the management of which is multi-faceted. Further evidence is needed to better understand and prioritize unmet needs and improve outcomes for patients with ET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.